Lancet: secukinumab vs adalimumab for psoriasis arthritis

THE EXCEED STUDY COMPARED THE EFFICACY AND SAFETY OF PATIENTS WITH PSORIASIS ARTHRITIS AT 52 WEEKS IN A HEAD-TO-HEAD TRIAL INVOLVING PATIENTS WITH PSORIASIS ARTHRITISstudies were conducted in 168 centres in 26 countries, involving at least 18-year-old patients with active psoriasis arthritis and being treated at random with secukinumab or adalimumabInject 300 mg secukinumab under the subcutaneous baseline, week 1, week 2, week 3 and week 4, and then inject every 4 weeks until week 48From the baseline check to week 50, adalimumab is injected every 2 weeksThe main result of the study was an improvement of at least 20% of patients at 52 weeks of ACR response standard (ACR20)853 patients participated in the study, of whom 426 received secukinumab, 427 received adalimumab and 83% completed the 52-week studyAt 52 weeks ago, 61 (14%) of the 426 patients in the secukinumab group stopped treatment, compared with 101 (24%) of the 427 patients in the adalimumab groupAt week 52, 67% of patients in the secukinumab group received a ACR20 response, compared with 62% in the Adalimumab group (OR: 1.30)The security of secukinumab and adalimumab is consistent with previous reports7 (2 per cent) of 426 patients in the secukinumab group and 6 (1 per cent) of 427 patients in the adalimumab group developed severe infectionOne case in the secukinumab group died of colon cancer, but was not related to the study of the drugstudies have found that secukinumab's treatment of psoriasis arthritis is comparable to that of adalimumab